Skip to main content
Log in

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

GW572016 is a dual EGFR-ErbB2 inhibitor that has promise as an anticancer agent. Two phase I studies were conducted to determine the safety, tolerability and pharmacokinetics of single and multiple doses given to healthy subjects. The single dose study evaluated two groups of eight subjects in an ascending dose, 4-way cross-over, while the multiple dose study evaluated twenty-seven healthy volunteers in an ascending dose, double-blind, randomized, placebo-controlled, staggered parallel design. No serious adverse events were seen in either study. The most common adverse events for subjects receiving GW572016 were headache, diarrhea, rash, cold symptoms, gastrointestinal symptoms, and elevated LFTs, which were similar between treatment and placebo groups. Absorption of single doses of GW572016 was slightly delayed, with median t l ag of 15 minutes (range 0–90 minutes) and achieved peak serum concentrations at a median of three hours (range 1.5–6 hours) post-dose. Serum concentrations after multiple doses of GW572016 demonstrated no significant accumulation at the 25 mg dose, and approximately 50% accumulation at the 100 mg and 175 mg doses, achieving steady state in six to seven days. A modest time-dependent increase in serum concentrations also was detected with multiple doses of GW572016. Single and multiple oral doses of GW572016 were well tolerated in healthy subjects, and resulted in dose-related systemic exposure of GW572016.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, Ono M: ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62(9): 2554-2560, 2002

    Google Scholar 

  2. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57(21): 4838-4848, 1997

    Google Scholar 

  3. Perry JE, Grossmann ME, Tindall DJ: Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate 35(2): 117-124, 1998

    Google Scholar 

  4. Shibata T, Kawano T, Nagayasu H, Okumura K, Arisue M, Hamada J, Takeichi N, Hosokawa M: Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol 17(3): 168-175, 1996

    Google Scholar 

  5. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2): 127-137, 2001

    Google Scholar 

  6. Huang GC, Hobbs S, Walton M, Epstein RJ: Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells. Br J Cancer 86(7): 1104-1109, doi: 1110.1038/sj/bjc/6600219, 2002

    Google Scholar 

  7. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 96(9): 4995-5000, 1999

    Google Scholar 

  8. Anzai H, Kitadai Y, Bucana CD, Sanchez R, Omoto R, Fidler IJ: Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence. Eur J Cancer 34(4): 558-565, 1998

    Google Scholar 

  9. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 15(8): 2894-2904, 1997

    Google Scholar 

  10. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11(10): 1936-1942, 1993

    Google Scholar 

  11. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785): 177-182, 1987

    Google Scholar 

  12. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4): S9-15, 2001

    Google Scholar 

  13. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM: EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196(1): 17-25, 2002

    Google Scholar 

  14. Simpson BJ, Phillips HA, Lessells AM, Langdon SP, Miller WR: c-erbB growth-factor-receptor proteins in ovarian tumours. Int J Cancer 64(3): 202-206, 1995

    Google Scholar 

  15. Cohen BD, Kiener PA, Green JM, Foy L, Fell HP, Zhang K: The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem 271(48): 30897-30903, 1996

    Google Scholar 

  16. Raymond E, Faivre S, Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60(Suppl 1): 15-23, 2000

    Google Scholar 

  17. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Holscher AH, Danenberg PV: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung.49 cancer Is correlated with survival. Clin Cancer Res 7(7): 1850-1855, 2001

    Google Scholar 

  18. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1(2): 85-94, 2001

    Google Scholar 

  19. Xia W, Mullin R, Keith B, Liu L-H, Ma H, Rusnak DW, Owens G, Alligood K, Spector NL: Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21: 6255-6363, 2002

    Google Scholar 

  20. Xia W, Liu L-H, Ho P, Spector NL: Truncated ErbB2 receptor (p95 ErbB2 )is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23: 646-653, 2004

    Google Scholar 

  21. Zhou H, Kim Y-S, Peletier A, McCall W, Earp HS, Sartor CI: Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR-and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiation Oncology Biol Phys 58(2): 334-352, 2004

    Google Scholar 

  22. Grana TM, Sartor CI, Cox AD: Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the ras oncogene enhances radiation resistance. Cancer Res 63: 7807-7814, 2003

    Google Scholar 

  23. Hsieh S, Tobien T, Koch K, Dunn J: Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development. Rapid Commun Mass Spectrom 18(3): 285-292, 2004

    Google Scholar 

  24. Gough K, Hutchinson M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J: Assessment of dose proportionality: Report from the statisticians in the pharmaceutical industry/pharmacokinetics UK Joint Working Party. Drug Inf J 29: 1039-1048, 1995

    Google Scholar 

  25. Hollander M, Wolfe DA: Nonparametric Statistical Methods. New York, John Wiley & Sons, 1973

    Google Scholar 

  26. Swaisland H, Laight A, Stafford L, Jones H, Morris C, Dane A, Yates R: Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 40(4): 297-306, 2001

    Google Scholar 

  27. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19(13): 3267-3279, 2001

    Google Scholar 

  28. Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW: Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 29(3 Suppl 11): 11-21, 2002

    Google Scholar 

  29. Garrison MA, Tolcher A, McCreery H, Rowinsky EK, Schott A, Mace J, Drengler R, Patnaik A, Denis L, Lenehan P, Eiseman I, Bycott P, Olson S, Baker L: A phase I and pharmacokinetic study of CI-1033, a pan-erbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors. (Abstract) Proc Am Soc Clin Oncol 20: 283, 2001

    Google Scholar 

  30. Rinehart JJ, Wilding G, Willson J, Krishnamurthi S, Natale R, Mani S, Burnett D, Olson S, Bycott P, Owens-Grillo JK, Hes M, Lenehan P: A phase I clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. (Abstract) Proc Am Soc Clin Oncol 21: 11, 2002

    Google Scholar 

  31. Shin DM, Nemunaitis J, Zinner RG, Donato NJ, Shin C, Myers JN, Zhang PS, Zentgraf RE, Khuri FR, Glisson BS, Eisenman I, Olson S, Bycott P, Lenehan PF, Hong WK: A phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors. (Abstract) Proc Am Soc Clin Oncol 20: 59, 2001

    Google Scholar 

  32. Negoro S, Nakagawa K, Fukuoka M, Kudoh S, Tamura T, Yoshimura N, Takeda K, Tanigawara Y, Swaisland H: Final results from a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumors. (Abstract) Proc Am Soc Clin Oncol 20: 324, 2001

    Google Scholar 

  33. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20(9): 2240-2250, 2002

    Google Scholar 

  34. Baselga J, Herbst R, LoRusso P, Rischin D, Ranson M, Plummer R, Raymond E, Maddox AM, Kaye S, Kieback D, Harris A, Ochs J: Continuous administration of ZD1839 ('Iressa'), a novel oral epidermal growth factor receptor tyrosine inhibitor (EGFR-TKI), in patients with five selected tumour types: Evidence of activity and good tolerability. (Abstract) Proc Am Soc Clin Oncol 19: 177, 2000

    Google Scholar 

  35. Burris HA, Taylor C, Jones S, Pandite L, Smith DA, Versola M, Stead A, Whitehead B, Spector N, Wilding G: A phase I study of GW572016 in patients with solid tumors. (Abstract) Proc Am Soc Clin Oncol 22: 248, 2003

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bence, A.K., Anderson, E.B., Halepota, M.A. et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 23, 39–49 (2005). https://doi.org/10.1023/B:DRUG.0000047104.45929.ea

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:DRUG.0000047104.45929.ea

Navigation